Biogen's Slow Rebound Prompts A Vetr Downgrade

The Vetr crowd on Tuesday downgraded their rating for Biogen Inc (NASDAQ: BIIB) from 5 stars (Strong Buy), issued five days ago, to 4 stars (Buy). Crowd sentiment for Biogen is unanimously positive, with 100 percent of Vetr user ratings bullish.

Share price in Biogen fell sharply in the first two days of February. It has slowly climbed about $5 since then, finishing Tuesday at $266.11.

Today also marked an upgrade from analysts with Citigroup, who raised Biogen's rating from Neutral to Buy.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $295.39, which is still below the average analyst target price of $332.00. Less than 2 percent of Vetr users are holding BIIB in their watch lists.

Latest Ratings for BIIB

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

See more from Benzinga

• D.R. Horton Gets A Strong Buy From Vetr

• Meet The Software Developer Who Brought His Entire Portfolio To A Single App

• Blackline Gets A Downgrade From Vetr Ahead Of Earnings Report

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.